Alkem Laboratories Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Developed by Prof. Claudio De Simone, DSS combines eight carefully selected bacterial strains in precise proportions, chosen for their unique biochemical and enzymatic profiles, to act synergistically on gastrointestinal physiology.

The formulation is backed by over 80 clinical trials and more than 200 scientific publications over the past two decades. It is also recommended by leading American and European gastroenterology associations for managing gastrointestinal disorders. Alkem has in-licensed the formulation from Next Gen Pharma India.

The DSS range will be available in four strengths: 225 billion CFU sachet, 112.5 billion CFU capsule, 45 billion CFU capsule, and 10 billion CFU capsule. Alkem becomes the first company in India to offer all four strengths and has exclusive marketing rights for the 225 billion CFU and 10 billion CFU variants.

The probiotic contains eight live, freeze-dried strains ? four Lactobacillus, three Bifidobacterium, and one Streptococcus ? designed to restore gut microbiota balance and provide clinically proven benefits.

DSS is indicated for managing disorders such as Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC), Pouchitis, Hepatic Encephalopathy (HE), Non-Alcoholic Fatty Liver Disease (NAFLD), Cirrhosis, Bacterial Vaginosis (BV), Antibiotic-Associated Diarrhea (AAD), and other gut dysbiosis-related conditions, as well as for supplementation during pregnancy and lactation.

According to IQVIA data (MAT October 2025), the prescription probiotic market in India is valued at around Rs 2,071 crore, and has recorded a five-year CAGR of approximately 14%.

Vikas Gupta, chief executive officer (CEO), Alkem, said, ?There is a growing focus on managing gut health as an integral part of overall well-being, and probiotics have emerged as a key enabler in this space. The launch of DSS, a globally-trusted, high-potent, multistrain probiotic, is a strategic addition to our comprehensive product portfolio in the gastrointestinal segment, and underscores our commitment to making innovative and evidence-based health solutions accessible to Indian patients.?

Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products.

The company?s consolidated net profit jumped 11.1% to Rs 765.06 crore in Q2 FY26, compared with Rs 688.64 crore posted in Q2 FY26. Net sales rose 17.2% YoY to Rs 4,000.99 crore in the quarter ended 30 September 2025.

Shares of Alkem Laboratories shed 0.96% to currently trade at Rs 5,645 on the BSE.

Powered by Capital Market - Live News

Net profit of Alkem Laboratories rose 11.10% to Rs 765.06 crore in the quarter ended September 2025 as against Rs 688.64 crore during the previous quarter ended September 2024. Sales rose 17.17% to Rs 4000.99 crore in the quarter ended September 2025 as against Rs 3414.67 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News

Alkem Laboratories Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 5853.5, up 1.49% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.28% on the day, quoting at 25949.3. The Sensex is at 84711.84, up 0.29%. Alkem Laboratories Ltd has added around 6.56% in last one month.

Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has added around 3.33% in last one month and is currently quoting at 22593.4, up 0.8% on the day. The volume in the stock stood at 2.13 lakh shares today, compared to the daily average of 1.28 lakh shares in last one month.

The benchmark November futures contract for the stock is quoting at Rs 5865.5, up 1.07% on the day. Alkem Laboratories Ltd is up 5.95% in last one year as compared to a 10.27% gain in NIFTY and a 4.7% gain in the Nifty Pharma index.

The PE of the stock is 32 based on TTM earnings ending June 25.

Powered by Capital Market - Live News

 Alkem Foundation, the Corporate Social Responsibility (CSR) arm of Alkem Laboratories (Alkem), and Indian Institute of Technology Bombay (IIT Bombay) today announced a strategic collaboration to set up a first-of-its-kind research centre in India dedicated to immuno-therapeutics and regenerative medicines.

Under this collaboration, Alkem Foundation will fund the establishment of ?Alkem Centre for Advanced Research and Development of Applied Immuno-Therapeutics and Regenerative Medicines? in the IIT Bombay campus. This is a pioneering step in fostering cutting-edge research and innovation in complex disease areas, which have significant unmet medical needs. Alkem Foundation will contribute a substantial 20-25% of its cumulative CSR obligations over seven years on this research centre.

This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines. The partnership brings together Alkem's pharmaceutical industry insights and experience in developing healthcare solutions, and IIT Bombay's expertise in biomedical engineering, biosciences, and translational research, along with a pool of globally trained faculty, to create a distinctive innovation and translation ecosystem.

Powered by Capital Market - Live News